Karim Sallam
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 4 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Karim Sallam’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A100967 · Current
Licensed to practise in California · since 2007 · expires 2027-06-30 · University of Pittsburgh School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$74,509
Medicare paid this office $74,509 for 162 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $25,398 | $106 |
| Critical care, first 30-74 minutes | 28 | $21,751 | $184 |
| Long return visit (40+ min) | 38 | $5,149 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $4,595 | $71 |
| Evaluation of lower heart chamber assist device | 16 | $3,764 | $35 |
See all 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $25,398 | $106 |
| Critical care, first 30-74 minutes | 28 | $21,751 | $184 |
| Long return visit (40+ min) | 38 | $5,149 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $4,595 | $71 |
| Evaluation of lower heart chamber assist device | 16 | $3,764 | $35 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,108 | $155 |
| New patient visit (60+ min) | 13 | $2,102 | $162 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,884 | $105 |
| Test for exercise-induced heart and lung stress | 13 | $779 | $60 |
Who their Medicare patients are
162 Original Medicare patients in 2024. Average age 70 · Under 65 22% · 85 and older 12% · Women 50% · Also on Medicaid 36% · Health risk score 2.75. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Heart failure 75% · Chronic kidney disease 59% · Atrial fibrillation 57% · Diabetes 56% · Coronary heart disease 56% · COPD 27% · Depression 27% · Stroke 21% · Dementia 17% · Cancer 15%.
The office billed $448,721, Medicare allowed $94,765 and paid $74,509; for 743 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 162 | 743 | 70 | 2.75 | $448,721 | $74,509 |
| 2023 | 270 | 820 | 73 | 2.74 | $482,958 | $76,618 |
| 2022 | 405 | 975 | 73 | 2.53 | $377,139 | $65,816 |
| 2021 | 348 | 922 | 72 | 2.56 | $490,003 | $82,524 |
| 2020 | 202 | 834 | 69 | 2.97 | $389,169 | $73,860 |
| 2019 | 287 | 927 | 73 | 2.93 | $395,021 | $78,428 |
| 2018 | 317 | 1,071 | 72 | 2.49 | $450,181 | $85,510 |
| 2017 | 359 | 1,185 | 71 | 2.44 | $364,298 | $71,950 |
| 2016 | 116 | 670 | 71 | 2.72 | $360,538 | $61,859 |
| 2015 | 32 | 214 | 70 | 3.35 | $81,621 | $15,307 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Critical care, first 30-74 minutes | 33 | $27,610 | $192 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $20,082 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $6,420 | $73 |
| Long return visit (40+ min) | 31 | $4,814 | $130 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,318 | $160 |
| Evaluation of lower heart chamber assist device | 14 | $2,743 | $35 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,928 | $107 |
| Return visit (30+ min) | 12 | $1,084 | $90 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 97 | $868 | $7 |
| Test for exercise-induced heart and lung stress | 12 | $745 | $62 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 21 | $503 | $24 |
2022: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $19,021 | $94 |
| Critical care, first 30-74 minutes | 19 | $13,704 | $196 |
| Long return visit (40+ min) | 38 | $6,826 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $6,488 | $66 |
| Evaluation of lower heart chamber assist device | 18 | $3,475 | $36 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,711 | $181 |
| Hospital discharge day management, more than 30 minutes | 20 | $1,964 | $98 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 217 | $1,842 | $7 |
| Test for exercise-induced heart and lung stress | 27 | $1,687 | $62 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 36 | $874 | $24 |
2021: 10 services
| Critical care, first 30-74 minutes | 35 | $27,307 | $199 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $21,335 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $8,098 | $184 |
| Long return visit (40+ min) | 31 | $4,851 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $4,448 | $66 |
| Hospital discharge day management, more than 30 minutes | 45 | $4,445 | $99 |
| Return visit (30+ min) | 21 | $1,613 | $77 |
| Evaluation of lower heart chamber assist device | 17 | $1,557 | $34 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 165 | $1,355 | $7 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 14 | $739 | $30 |
2020: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $23,942 | $97 |
| Critical care, first 30-74 minutes | 28 | $18,478 | $203 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $5,879 | $68 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,320 | $190 |
| Evaluation of lower heart chamber assist device | 21 | $5,005 | $43 |
| Long return visit (40+ min) | 28 | $3,676 | $99 |
| Hospital discharge day management, more than 30 minutes | 21 | $2,237 | $102 |
| Return visit (30+ min) | 16 | $1,198 | $70 |
| Hospital discharge day management, 30 minutes or less | 11 | $801 | $67 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 13 | $723 | $31 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 49 | $476 | $8 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 14 | $347 | $25 |
2019: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $22,027 | $94 |
| Critical care, first 30-74 minutes | 27 | $19,297 | $197 |
| Long return visit (40+ min) | 52 | $7,959 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,892 | $184 |
| Evaluation of lower heart chamber assist device | 30 | $5,258 | $42 |
| Hospital discharge day management, more than 30 minutes | 28 | $2,776 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,772 | $66 |
| Insertion of tube in right heart chambers for measurement | 12 | $1,379 | $115 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,361 | $124 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,283 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 118 | $1,041 | $8 |
| Programming of multiple lead implantable defibrillator system | 11 | $822 | $55 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 13 | $343 | $25 |
2018: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 77 | $27,899 | $93 |
| Critical care, first 30-74 minutes | 24 | $20,774 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,977 | $181 |
| Evaluation of lower heart chamber assist device | 33 | $7,330 | $40 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $4,837 | $65 |
| Long return visit (40+ min) | 26 | $3,049 | $92 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,778 | $99 |
| Return visit (30+ min) | 19 | $1,413 | $64 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,203 | $67 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 131 | $1,146 | $8 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 40 | $981 | $25 |
2017: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $24,772 | $93 |
| Evaluation of lower heart chamber assist device | 34 | $11,782 | $41 |
| Critical care, first 30-74 minutes | 21 | $11,580 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $4,923 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,988 | $181 |
| Long return visit (40+ min) | 25 | $3,102 | $97 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 251 | $2,269 | $8 |
| Return visit (30+ min) | 24 | $1,966 | $70 |
| Hospital discharge day management, 30 minutes or less | 16 | $1,126 | $66 |
2016: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $20,092 | $93 |
| Critical care, first 30-74 minutes | 19 | $15,459 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,949 | $180 |
| Evaluation of lower heart chamber assist device | 20 | $5,888 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $5,144 | $64 |
| Hospital discharge day management, 30 minutes or less | 36 | $2,432 | $66 |
| Return visit (30+ min) | 14 | $911 | $65 |
2015: 1 service
| Evaluation of lower heart chamber assist device | 20 | $3,423 | $41 |
Medicaid work
$3,880 in 2024
Medicaid paid $3,880 for 59 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 59 | $3,880 |
| 2024 | 59 | 1 | 12 | $3,880 |
| 2023 | 111 | 1 | 55 | $1,080 |
| 2022 | 266 | 3 | 160 | $6,117 |
| 2021 | 202 | 2 | 115 | $3,157 |
| 2020 | 50 | 1 | 42 | $644 |
| 2019 | 74 | 1 | 67 | $940 |
| 2018 | 120 | 2 | 71 | $3,951 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 111 | $1,080 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 68 | $3,890 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 183 | $2,039 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 15 | $187 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 161 | $1,658 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 41 | $1,500 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 50 | $644 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 74 | $940 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 39 | $2,705 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 81 | $1,246 |
Drugs they prescribed that Part D paid
$530,531
Pharmacies billed $530,531 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,287) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
1,036 generic and 251 brand-name prescriptions · $530,531 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Camzyos | 29 | $265,516 | $9,156 |
| Entresto | 52 | $51,644 | $993 |
| Eliquis | 44 | $49,964 | $1,136 |
| Farxiga | 42 | $47,665 | $1,135 |
| Jardiance | 34 | $46,786 | $1,376 |
See all 33 drugs
| Camzyos | 29 | $265,516 | $9,156 |
| Entresto | 52 | $51,644 | $993 |
| Eliquis | 44 | $49,964 | $1,136 |
| Farxiga | 42 | $47,665 | $1,135 |
| Jardiance | 34 | $46,786 | $1,376 |
| Sirolimus | 51 | $8,738 | $171 |
| Tacrolimus | 78 | $7,134 | $91 |
| Mycophenolate Mofetil | 25 | $5,990 | $240 |
| Potassium Chloride | 32 | $5,288 | $165 |
| Vascepa | 11 | $3,421 | $311 |
| Rosuvastatin | 61 | $1,049 | $17 |
| Atorvastatin | 69 | $1,043 | $15 |
| Carvedilol | 89 | $894 | $10 |
| Eplerenone | 20 | $865 | $43 |
| Bumetanide | 12 | $816 | $68 |
| Pantoprazole | 46 | $801 | $17 |
| Diltiazem 24hr Er (Cd) | 25 | $694 | $28 |
| Spironolactone | 73 | $660 | $9 |
| Losartan | 30 | $590 | $20 |
| Febuxostat | 12 | $515 | $43 |
| Amiodarone | 13 | $503 | $39 |
| Metoprolol | 35 | $336 | $10 |
| Warfarin | 12 | $246 | $20 |
| Ezetimibe | 17 | $243 | $14 |
| Acyclovir | 31 | $211 | $7 |
| Famotidine | 16 | $174 | $11 |
| Amlodipine Besylate | 62 | $152 | $2 |
| Digoxin | 11 | $148 | $13 |
| Furosemide | 36 | $126 | $4 |
| Lisinopril | 13 | $71 | $5 |
| Gabapentin | 20 | $71 | $4 |
| Amoxicillin | 14 | $48 | $3 |
| Finasteride | 12 | $13 | $1 |
Year by year
| 2024 | 1,287 | 176 | 0% (0) | 20% | $530,531 |
| 2023 | 1,122 | 165 | 0% (0) | 18% | $259,159 |
| 2022 | 981 | 160 | None | None | $248,077 |
| 2021 | 861 | 135 | 0% (0) | None | $207,550 |
| 2020 | 830 | 132 | 0% (0) | 18% | $132,027 |
| 2019 | 719 | 117 | 0% (0) | None | $95,362 |
| 2018 | 684 | 102 | None | None | $81,380 |
| 2017 | 462 | 80 | 0% (0) | None | $27,655 |
| 2016 | 217 | 48 | None | 20% | $16,090 |
| 2015 | 131 | 38 | 0% (0) | None | $6,030 |
| 2014 | 64 | 26 | None | 22% | $5,038 |
| 2013 | 71 | 16 | 0% (0) | 23% | $2,598 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 31 drugs
| Entresto | 46 | $43,288 | $941 |
| Farxiga | 32 | $40,850 | $1,277 |
| Eliquis | 34 | $30,583 | $899 |
| Jardiance | 18 | $26,404 | $1,467 |
| Sirolimus | 46 | $23,554 | $512 |
| Envarsus Xr | 16 | $11,717 | $732 |
| Tacrolimus | 37 | $5,506 | $149 |
| Potassium Chloride | 37 | $3,669 | $99 |
| Eplerenone | 27 | $3,667 | $136 |
| Bumetanide | 25 | $1,888 | $76 |
| Rosuvastatin | 75 | $1,359 | $18 |
| Metoprolol | 40 | $1,351 | $34 |
| Mycophenolate Mofetil | 18 | $1,347 | $75 |
| Carvedilol | 58 | $1,252 | $22 |
| Digoxin | 11 | $1,154 | $105 |
| Atorvastatin | 49 | $937 | $19 |
| Pantoprazole | 41 | $898 | $22 |
| Ezetimibe | 16 | $874 | $55 |
| Diltiazem 24hr Er (Cd) | 32 | $770 | $24 |
| Spironolactone | 63 | $754 | $12 |
| Febuxostat | 12 | $555 | $46 |
| Hydralazine | 13 | $491 | $38 |
| Amlodipine Besylate | 47 | $449 | $10 |
| Acyclovir | 13 | $408 | $31 |
| Losartan | 17 | $318 | $19 |
| Famotidine | 27 | $172 | $6 |
| Finasteride | 13 | $167 | $13 |
| Furosemide | 23 | $159 | $7 |
| Lisinopril | 16 | $92 | $6 |
| Gabapentin | 11 | $78 | $7 |
| Hydrochlorothiazide | 12 | $30 | $2 |
2022: 23 drugs
| Eliquis | 56 | $53,420 | $954 |
| Entresto | 53 | $49,064 | $926 |
| Farxiga | 33 | $35,889 | $1,088 |
| Sirolimus | 43 | $19,418 | $452 |
| Jardiance | 11 | $12,726 | $1,157 |
| Disopyramide Phosphate | 13 | $5,924 | $456 |
| Tacrolimus | 23 | $2,561 | $111 |
| Ezetimibe | 11 | $2,289 | $208 |
| Bumetanide | 20 | $1,853 | $93 |
| Metoprolol | 54 | $1,278 | $24 |
| Carvedilol | 70 | $1,190 | $17 |
| Rosuvastatin | 46 | $1,004 | $22 |
| Pantoprazole | 39 | $846 | $22 |
| Spironolactone | 50 | $694 | $14 |
| Atorvastatin | 39 | $588 | $15 |
| Losartan | 20 | $466 | $23 |
| Amlodipine Besylate | 38 | $405 | $11 |
| Furosemide | 30 | $345 | $12 |
| Diltiazem 24hr Er (Cd) | 15 | $297 | $20 |
| Flecainide Acetate | 11 | $155 | $14 |
| Famotidine | 14 | $142 | $10 |
| Hydrochlorothiazide | 22 | $86 | $4 |
| Lisinopril | 16 | $77 | $5 |
2021: 22 drugs
| Entresto | 55 | $47,705 | $867 |
| Eliquis | 41 | $42,980 | $1,048 |
| Farxiga | 28 | $28,074 | $1,003 |
| Sirolimus | 26 | $11,806 | $454 |
| Bumetanide | 20 | $1,679 | $84 |
| Amiodarone | 20 | $1,650 | $83 |
| Metoprolol | 46 | $1,269 | $28 |
| Tacrolimus | 20 | $1,049 | $52 |
| Carvedilol | 75 | $930 | $12 |
| Atorvastatin | 39 | $691 | $18 |
| Rosuvastatin | 23 | $578 | $25 |
| Spironolactone | 50 | $558 | $11 |
| Flecainide Acetate | 11 | $510 | $46 |
| Losartan | 26 | $445 | $17 |
| Pantoprazole | 24 | $441 | $18 |
| Amlodipine Besylate | 27 | $343 | $13 |
| Furosemide | 29 | $210 | $7 |
| Gabapentin | 14 | $173 | $12 |
| Warfarin | 12 | $145 | $12 |
| Lisinopril | 17 | $136 | $8 |
| Acyclovir | 11 | $88 | $8 |
| Hydrochlorothiazide | 16 | $43 | $3 |
2020: 23 drugs
| Eliquis | 37 | $38,121 | $1,030 |
| Entresto | 23 | $20,848 | $906 |
| Envarsus Xr | 12 | $6,388 | $532 |
| Sirolimus | 12 | $3,874 | $323 |
| Bumetanide | 25 | $1,887 | $75 |
| Tacrolimus | 20 | $1,262 | $63 |
| Diltiazem 24hr Er (Cd) | 19 | $1,111 | $58 |
| Amiodarone | 19 | $1,072 | $56 |
| Rosuvastatin | 31 | $1,011 | $33 |
| Carvedilol | 63 | $723 | $11 |
| Metoprolol | 33 | $715 | $22 |
| Atorvastatin | 37 | $640 | $17 |
| Spironolactone | 56 | $563 | $10 |
| Losartan | 34 | $513 | $15 |
| Hydralazine | 29 | $405 | $14 |
| Gabapentin | 12 | $328 | $27 |
| Furosemide | 29 | $255 | $9 |
| Amlodipine Besylate | 36 | $246 | $7 |
| Warfarin | 11 | $244 | $22 |
| Levothyroxine | 13 | $238 | $18 |
| Pantoprazole | 12 | $151 | $13 |
| Isosorbide Mononitrate Er | 12 | $150 | $12 |
| Lisinopril | 13 | $112 | $9 |
2019: 20 drugs
| Entresto | 19 | $21,399 | $1,126 |
| Eliquis | 32 | $20,879 | $652 |
| Disopyramide Phosphate | 13 | $3,225 | $248 |
| Bumetanide | 21 | $1,809 | $86 |
| Rosuvastatin | 17 | $884 | $52 |
| Atorvastatin | 34 | $772 | $23 |
| Carvedilol | 52 | $605 | $12 |
| Spironolactone | 55 | $605 | $11 |
| Diltiazem 24hr Er (Cd) | 15 | $559 | $37 |
| Metoprolol | 14 | $542 | $39 |
| Digoxin | 16 | $422 | $26 |
| Amlodipine Besylate | 50 | $362 | $7 |
| Hydralazine | 22 | $360 | $16 |
| Losartan | 28 | $327 | $12 |
| Pantoprazole | 18 | $274 | $15 |
| Warfarin | 20 | $195 | $10 |
| Lisinopril | 21 | $177 | $8 |
| Metoprolol | 17 | $174 | $10 |
| Furosemide | 19 | $151 | $8 |
| Isosorbide Mononitrate Er | 11 | $130 | $12 |
2018: 22 drugs
| Teflaro | 12 | $31,339 | $2,612 |
| Eliquis | 11 | $7,346 | $668 |
| Verapamil | 14 | $2,773 | $198 |
| Verapamil Er | 13 | $752 | $58 |
| Potassium Chloride | 14 | $620 | $44 |
| Digoxin | 14 | $529 | $38 |
| Rosuvastatin | 16 | $503 | $31 |
| Atorvastatin | 47 | $454 | $10 |
| Carvedilol | 46 | $427 | $9 |
| Isosorbide Mononitrate Er | 21 | $381 | $18 |
| Diltiazem 24hr Er | 16 | $356 | $22 |
| Warfarin | 29 | $356 | $12 |
| Gabapentin | 12 | $341 | $28 |
| Pravastatin | 14 | $330 | $24 |
| Spironolactone | 24 | $326 | $14 |
| Hydralazine | 13 | $264 | $20 |
| Amiodarone | 17 | $229 | $13 |
| Losartan | 31 | $228 | $7 |
| Amlodipine Besylate | 44 | $188 | $4 |
| Furosemide | 36 | $177 | $5 |
| Pantoprazole | 17 | $141 | $8 |
| Metoprolol | 13 | $57 | $4 |
2017: 13 drugs
| Digoxin | 11 | $569 | $52 |
| Pravastatin | 16 | $437 | $27 |
| Metoprolol | 17 | $414 | $24 |
| Warfarin | 30 | $400 | $13 |
| Potassium Chloride | 12 | $392 | $33 |
| Levothyroxine | 14 | $383 | $27 |
| Atorvastatin | 18 | $334 | $19 |
| Carvedilol | 38 | $279 | $7 |
| Amiodarone | 12 | $251 | $21 |
| Spironolactone | 13 | $224 | $17 |
| Furosemide | 34 | $166 | $5 |
| Amlodipine Besylate | 21 | $105 | $5 |
| Lisinopril | 14 | $58 | $4 |
2016: 5 drugs
| Amiodarone | 12 | $684 | $57 |
| Hydralazine | 12 | $419 | $35 |
| Warfarin | 19 | $282 | $15 |
| Carvedilol | 17 | $103 | $6 |
| Furosemide | 16 | $52 | $3 |
2015: 2 drugs
| Carvedilol | 15 | $210 | $14 |
| Atorvastatin | 11 | $129 | $12 |
2014: 1 drug
| Atorvastatin | 13 | $155 | $12 |
2013: 1 drug
| Enalapril Maleate | 11 | $43 | $4 |
Money from drug and device companies
$43 in 2025
| 2025 | 1 | 1 | None | $43 |
| 2024 | 1 | 3 | None | $78 |
| 2022 | 1 | 3 | None | $78 |
| 2021 | 2 | 8 | None | $251 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| CVRx | Barostim Neo System | $43 | 1 payment
|
See the published payment
| CVRx | Meals · 2025-07-14 | Barostim Neo System | $43 |
See earlier years (2024, 2022, 2021)
2024: $78
| Abiomed | Impella | $78 | 3 payments
|
2022: $78
| Saranas | None | $78 | 3 payments
|
2021: $251
| Saranas | None | $148 | 6 payments
|
| Shockwave Medical | Vascular Lithotripsy | $103 | 2 payments
|
Professional record
- NPI
- 1790968436
- Licence
- CA A100967California A100967: Current · expires 2027-06-30
- Trained
- University of Pittsburgh School of Medicine, 2006
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0001X (207RA0001X); Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-12-17
- NPI last updated
- 2024-04-24
- NPI record certified
- 2024-04-24
This is when the NPI record was last certified, not a medical board exam.